Zhu Qian, Zhou Qu, Luo Xiao-Li, Zhang Xu-Jie, Li San-Yu
Department of Pharmacy, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
Parexel China Co., Ltd., Chengdu 610000, China.
Korean J Physiol Pharmacol. 2023 May 1;27(3):221-230. doi: 10.4196/kjpp.2023.27.3.221.
Diabetic kidney disease is one of the most serious complications of diabetes. Although diabetic kidney disease can be effectively controlled through strict blood glucose management and corresponding symptomatic treatment, these therapies cannot reduce its incidence in diabetic patients. The sodium-glucose cotransporter 2 (SGLT2) inhibitors and the traditional Chinese herb "" have been widely used in diabetes-related therapy. However, it remains unclear whether the combined use of these two kinds of medicines contributes to an increased curative effect on diabetic kidney disease. In this study, we examined this issue by evaluating the efficacy of the combination of puerarin, an active ingredient of Gegen, and canagliflozin, an SGLT2 inhibitor for a 12-week intervention using a mouse model of diabetes. The results indicated that the combination of puerarin and canagliflozin was superior to canagliflozin alone in improving the metabolic and renal function parameters of diabetic mice. Our findings suggested that the renoprotective effect of combined puerarin and canagliflozin in diabetic mice was achieved by reducing renal lipid accumulation. This study provides a new strategy for the clinical prevention and treatment of diabetic kidney disease. The puerarin and SGLT2 inhibitor combination therapy at the initial stage of diabetes may effectively delay the occurrence of diabetic kidney injury, and significantly alleviate the burden of renal lipotoxicity.
糖尿病肾病是糖尿病最严重的并发症之一。尽管通过严格的血糖管理和相应的对症治疗可以有效控制糖尿病肾病，但这些疗法并不能降低其在糖尿病患者中的发病率。钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和中药“ ”已广泛应用于糖尿病相关治疗。然而，这两种药物联合使用是否有助于提高糖尿病肾病的疗效仍不清楚。在本研究中，我们通过使用糖尿病小鼠模型评估葛根活性成分葛根素与SGLT2抑制剂卡格列净联合用药12周的干预效果来研究这个问题。结果表明，葛根素与卡格列净联合使用在改善糖尿病小鼠的代谢和肾功能参数方面优于单独使用卡格列净。我们的研究结果表明，葛根素与卡格列净联合使用对糖尿病小鼠的肾脏保护作用是通过减少肾脏脂质蓄积实现的。本研究为糖尿病肾病的临床防治提供了新策略。在糖尿病初期采用葛根素与SGLT2抑制剂联合治疗可能有效延缓糖尿病肾损伤的发生，并显著减轻肾脏脂毒性负担。
